Physician profile
Mark D Purcell
NPI 1639183544
$164,709.43
in general payments reported to CMS, 2019-2025
31 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $651 · 2021: $15K · 2022: $34K · 2023: $35K · 2024: $47K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Travel and Lodging: $6,514 · Food and Beverage: $5,745 · Education: $71.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,030.00 |
| Travel and Lodging | $6,514.32 |
| Food and Beverage | $5,744.65 |
| Education | $71.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $82,142.56 | 2019-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $43,444.94 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,169.65 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,315.00 | 2020-2021 | |
| Horizon Therapeutics Plc | $651.52 | 2019-2023 | Krystexxa |
| Amgen INC. | $650.13 | 2020-2025 | Krystexxa, Tavneos, Uplizna |
| Novartis Pharmaceuticals Corporation | $526.42 | 2024-2025 | |
| Travere Therapeutics, INC. | $472.37 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $470.40 | 2021-2024 | |
| Vifor Pharma, INC. | $313.94 | 2020-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $313.44 | 2020-2025 | Terlivaz, Acthar |
| Akebia Therapeutics INC | $309.40 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $267.47 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $214.26 | 2019-2024 | Benlysta, Jesduvroq, Arexvy |
| Calliditas Therapeutics US INC. | $183.43 | 2024-2025 | Tarpeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $179.46 | 2022-2024 | |
| Baxter Healthcare | $177.13 | 2019 | |
| Novo Nordisk INC | $148.06 | 2024-2025 | Ozempic, Rybelsus, Rivfloza |
| Outset Medical INC | $137.52 | 2025 | |
| Bard Peripheral Vascular, INC. | $121.46 | 2019 | |
| Opko Pharmaceuticals, LLC | $114.63 | 2019-2023 | Rayaldee |
| Ani Pharmaceuticals, INC. | $79.37 | 2022-2023 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $72.08 | 2022-2023 | Lupkynis |
| Fresenius USA Marketing, INC. | $60.83 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $41.08 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $28.47 | 2022 | |
| Rockwell Medical, INC. | $23.77 | 2020 | |
| Daiichi Sankyo INC. | $23.65 | 2024 | Injectafer |
| Lundbeck LLC | $20.87 | 2019 | |
| Genentech USA, INC. | $20.21 | 2025 | Gazyva |
| Biomerieux INC | $15.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.